Capital Guardian Trust Co. acquired a new stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 833,695 shares of the biopharmaceutical company’s stock, valued at approximately $37,400,000. Capital Guardian Trust Co. owned about 0.73% of Juno Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Capital International Ltd. CA acquired a new stake in shares of Juno Therapeutics during the 3rd quarter worth about $14,777,000. Janus Henderson Group PLC acquired a new stake in shares of Juno Therapeutics during the 3rd quarter worth about $37,351,000. Capital International Inc. CA acquired a new stake in shares of Juno Therapeutics during the 3rd quarter worth about $2,467,000. L & S Advisors Inc acquired a new stake in shares of Juno Therapeutics during the 3rd quarter worth about $615,000. Finally, Asset Management One Co. Ltd. acquired a new stake in shares of Juno Therapeutics during the 3rd quarter worth about $2,395,000. 70.37% of the stock is currently owned by hedge funds and other institutional investors.

In related news, EVP Robert Azelby sold 6,666 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the transaction, the executive vice president now owns 79,998 shares in the company, valued at $4,395,890.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sunil Agarwal sold 7,285 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Insiders sold 54,801 shares of company stock worth $2,527,741 in the last 90 days. 15.08% of the stock is currently owned by insiders.

Juno Therapeutics, Inc. (NASDAQ JUNO) opened at $58.65 on Monday. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $63.45. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the firm posted ($0.57) earnings per share. Juno Therapeutics’s revenue for the quarter was up 115.4% compared to the same quarter last year. analysts expect that Juno Therapeutics, Inc. will post -4.02 EPS for the current year.

Several research analysts have recently weighed in on JUNO shares. Cowen reiterated a “buy” rating and set a $49.00 price objective on shares of Juno Therapeutics in a report on Friday, October 27th. Maxim Group reiterated a “buy” rating and set a $56.00 price objective (up from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Citigroup reiterated a “buy” rating and set a $59.00 price objective on shares of Juno Therapeutics in a report on Tuesday, October 31st. SunTrust Banks upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $43.00 price objective (up from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $45.48.

TRADEMARK VIOLATION NOTICE: “Capital Guardian Trust Co. Invests $37.40 Million in Juno Therapeutics, Inc. (JUNO) Stock” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/capital-guardian-trust-co-invests-37-40-million-in-juno-therapeutics-inc-juno-stock/1756934.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.